Peringatan Keamanan

Risk factor D in pregnancy. It is not known if romidepsin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.
The majority of patients receiving romidepsin experience nausea, vomiting, and anorexia.

Romidepsin

DB06176

small molecule approved investigational

Deskripsi

Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.

Struktur Molekul 2D

Berat 540.69
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 3 hours
Volume Distribusi 44.5L
Klirens (Clearance) 8.4L/h

Absorpsi

Romidepsin exhibited linear pharmacokinetics at standard doses.

Metabolisme

Romidepsin undergoes extensive hepatic metabolism in vitro primarily by CYP3A4 with minor contribution from CYP3A5, CYP1A1, CYP2B6 and CYP2C19.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of romidepsin.
  • 2. Avoid St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of romidepsin.

Interaksi Obat

975 Data
Modafinil The metabolism of Romidepsin can be increased when combined with Modafinil.
Armodafinil The metabolism of Romidepsin can be increased when combined with Armodafinil.
Ranolazine The serum concentration of Romidepsin can be increased when it is combined with Ranolazine.
Metreleptin The metabolism of Romidepsin can be increased when combined with Metreleptin.
Vorinostat The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Romidepsin is combined with Vorinostat.
Warfarin Romidepsin may increase the anticoagulant activities of Warfarin.
Acenocoumarol Romidepsin may increase the anticoagulant activities of Acenocoumarol.
(R)-warfarin Romidepsin may increase the anticoagulant activities of (R)-warfarin.
R,S-Warfarin alcohol Romidepsin may increase the anticoagulant activities of R,S-Warfarin alcohol.
S,R-Warfarin alcohol Romidepsin may increase the anticoagulant activities of S,R-Warfarin alcohol.
(S)-Warfarin Romidepsin may increase the anticoagulant activities of (S)-Warfarin.
Crizotinib The metabolism of Romidepsin can be decreased when combined with Crizotinib.
Rifampin The serum concentration of Romidepsin can be increased when it is combined with Rifampicin.
Lumacaftor The serum concentration of Romidepsin can be decreased when it is combined with Lumacaftor.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Romidepsin.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Romidepsin.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Romidepsin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Romidepsin.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Romidepsin.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Romidepsin.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Romidepsin.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Romidepsin.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Romidepsin.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Romidepsin.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Romidepsin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Romidepsin.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Romidepsin.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Romidepsin.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Romidepsin.
Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Romidepsin.
Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Romidepsin.
Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Romidepsin.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Romidepsin.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Romidepsin.
Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Romidepsin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Romidepsin.
Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Romidepsin.
Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Romidepsin.
Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Romidepsin.
Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Romidepsin.
Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Romidepsin.
Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Romidepsin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Romidepsin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Romidepsin.
Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Romidepsin.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Romidepsin.
Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Romidepsin.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Romidepsin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Romidepsin.
Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Romidepsin.
Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Romidepsin.
Aceprometazine The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Romidepsin.
Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Romidepsin.
Prenylamine The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Romidepsin.
Fluspirilene The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Romidepsin.
Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Romidepsin.
Azimilide The risk or severity of QTc prolongation can be increased when Azimilide is combined with Romidepsin.
Pracinostat The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Romidepsin.
Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Romidepsin.
Garenoxacin The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Romidepsin.
Tedisamil The risk or severity of QTc prolongation can be increased when Tedisamil is combined with Romidepsin.
Tucidinostat The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Romidepsin.
Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Romidepsin.
Nemonoxacin The risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Romidepsin.
Panobinostat The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Romidepsin.
Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Romidepsin.
Bedaquiline The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Bedaquiline.
Fendiline The risk or severity of QTc prolongation can be increased when Fendiline is combined with Romidepsin.
Eperisone The risk or severity of QTc prolongation can be increased when Eperisone is combined with Romidepsin.
Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Romidepsin.
Melperone The risk or severity of QTc prolongation can be increased when Melperone is combined with Romidepsin.
Dexchlorpheniramine maleate The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Romidepsin.
Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Romidepsin.
Mocetinostat The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Romidepsin.
Entinostat The risk or severity of QTc prolongation can be increased when Entinostat is combined with Romidepsin.
Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Romidepsin.
CUDC-101 The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Romidepsin.
Simendan The risk or severity of QTc prolongation can be increased when Simendan is combined with Romidepsin.
Ricolinostat The risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Romidepsin.
Mizolastine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Romidepsin.
Abexinostat The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Romidepsin.
Oxatomide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Romidepsin.
Sitafloxacin The risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Romidepsin.
Sultopride The risk or severity of QTc prolongation can be increased when Sultopride is combined with Romidepsin.
Otilonium The risk or severity of QTc prolongation can be increased when Otilonium is combined with Romidepsin.
Nizofenone The risk or severity of QTc prolongation can be increased when Nizofenone is combined with Romidepsin.
Bunaftine The risk or severity of QTc prolongation can be increased when Bunaftine is combined with Romidepsin.
Lorcainide The risk or severity of QTc prolongation can be increased when Lorcainide is combined with Romidepsin.
Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Romidepsin.
Penfluridol The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Romidepsin.
Dexverapamil The risk or severity of QTc prolongation can be increased when Dexverapamil is combined with Romidepsin.
Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Romidepsin.
Levacetylmethadol The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Romidepsin.
Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Romidepsin.
Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Romidepsin.
Clomipramine The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Romidepsin.
Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Romidepsin.
Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Romidepsin.
Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Romidepsin.
Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Romidepsin.

Target Protein

Histone deacetylase 1 HDAC1
Histone deacetylase 2 HDAC2
Histone deacetylase 4 HDAC4
Histone deacetylase 6 HDAC6
Multidrug resistance-associated protein 1 ABCC1
Histone deacetylase HDAC1

Referensi & Sumber

Synthesis reference: Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994 Mar;47(3):301-10. Pubmed(http://www.ncbi.nlm.nih.gov/pubmed/7513682).
Artikel (PubMed)
  • PMID: 21587264
    VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011 Aug;64(8):525-31. doi: 10.1038/ja.2011.35. Epub 2011 May 18.
  • PMID: 26473529
    Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS: Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015 Oct 16;5:e357. doi: 10.1038/bcj.2015.83.

Contoh Produk & Brand

Produk: 9 • International brands: 2
Produk
  • Istodax
    Kit • 10 mg/2mL • Intravenous • US • Approved
  • Istodax
    Injection, powder, lyophilized, for solution; Kit • 10 mg/2mL • Intravenous • US • Approved
  • Istodax
    Injection, powder, lyophilized, for solution; Kit • 10 mg/2mL • Intravenous • US • Approved
  • Istodax
    Kit; Powder, for solution • 10 mg / vial • Intravenous • Canada • Approved
  • Romidepsin
    Kit • 10 mg/2mL • Intravenous • US • Generic • Approved
  • Romidepsin
    Injection, solution, concentrate • 5 mg/1mL • Intravenous • US • Approved
  • Romidepsin
    Kit • 10 mg/2mL • Intravenous • US • Generic • Approved
  • Romidepsin
    Injection, solution, concentrate • 5 mg/1mL • Intravenous • US • Approved
Menampilkan 8 dari 9 produk.
International Brands
  • Chromadax
  • Istodax

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul